Emerging evidence indicates JAK inhibitors could be a valuable alternative for managing checkpoint inhibitor–induced immune toxicities, especially in difficult-to-treat cases.

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

EXCLUSIVE: New mum Zara was shattered when told she had bowel cancer, but a new drug trial at The Christie in Manchester has ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

A team of researchers has identified a potential new strategy to prevent, or even reverse, immune checkpoint ...

Researchers are working to launch a first-in-human clinical trial to test the approach in patients with cancer who develop diabetes after immunotherapy.

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type ...